Humira Biosimilars Not Gaining Traction Shows Dysfunctional US System
Impediments to biosimilar access prevent market competition from working properly, raise patient cost-sharing and harm long-term sustainability of biosimilar development.
United States Senate Finance Committee Cardinal Health European Medicines Agency Biosimilar Forum National Institute For Health
Source: forbes.com